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A B S T R A C T
Purpose
The genetic basis of myelodysplastic syndromes (MDS) is heterogeneous, and various combina-
tions of somaticmutations are associatedwith different clinical phenotypes and outcomes.Whether
the genetic basis of MDS influences the outcome of allogeneic hematopoietic stem-cell trans-
plantation (HSCT) is unclear.
Patients and Methods
We studied 401 patients with MDS or acute myeloid leukemia (AML) evolving from MDS (MDS/
AML).We usedmassively parallel sequencing to examine tumor samples collected before HSCT for
somatic mutations in 34 recurrently mutated genes in myeloid neoplasms. We then analyzed the
impact of mutations on the outcome of HSCT.
Results
Overall, 87% of patients carried one or more oncogenic mutations. Somatic mutations of ASXL1,
RUNX1, and TP53 were independent predictors of relapse and overall survival after HSCT in both
patients withMDS and patients withMDS/AML (P values ranging from .003 to .035). In patients with
MDS/AML, gene ontology (ie, secondary-type AML carrying mutations in genes of RNA splicing
machinery, TP53-mutated AML, or de novo AML)was an independent predictor of posttransplantation
outcome (P = .013). The impact of ASXL1, RUNX1, and TP53 mutations on posttransplantation
survival was independent of the revised International Prognostic Scoring System (IPSS-R).
Combining somatic mutations and IPSS-R risk improved the ability to stratify patients by cap-
turing more prognostic information at an individual level. Accounting for various combinations of
IPSS-R risk and somatic mutations, the 5-year probability of survival after HSCT ranged from 0%
to 73%.
Conclusion
Somatic mutation in ASXL1, RUNX1, or TP53 is independently associated with unfavorable out-
comes and shorter survival after allogeneic HSCT for patients with MDS andMDS/AML. Accounting
for these genetic lesions may improve the prognostication precision in clinical practice and in
designing clinical trials.
J Clin Oncol 34:3627-3637. © 2016 by American Society of Clinical Oncology
INTRODUCTION
Myelodysplastic syndromes (MDS) are myeloid
neoplasms that range from conditions with
a near-normal life expectancy to forms that are
close to acute myeloid leukemia (AML).1 Their
clinical heterogeneity reflects different somatic
mutations that cause clonal proliferation and
evolution of myelodysplastic cells.2-4
The fact that MDS have highly variable
clinical courses makes risk stratification of cru-
cial importance in clinical decision making.1,5
Several prognostic scoring systems based on
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clinical/hematologic parameters have been developed.6 In 2012,
an international collaborative group created the revised In-
ternational Prognostic Scoring System (IPSS-R), which defines
five risk groups with different probabilities of survival and leu-
kemic evolution.7
The only curative treatment for patients with MDS is allo-
geneic hematopoietic stem-cell transplantation (HSCT), which is
considered as a therapeutic option until the age of 65 to 70 years in
eligible patients.5 The long-term survival rate is currently ap-
proximately 30%.8-12 Reasons for transplantation failure include
toxicity of the procedure and disease relapse.
Prognostic scoring systems are currently used to predict the
outcome after HSCT.5,12 In particular, disease burden and cyto-
genetic abnormalities provide information on the risk of disease
relapse after the procedure.8-12 Major limitations of the use of these
scores include the reliability of some variables based on mor-
phologic evaluation and the fact that cytogenetics is not in-
formative in a large proportion of patients and includes secondary,
late genomic events, deriving from the genome instability caused
by the founding genetic mutation.4,13
Mutations in several genes have been reported to influence the
risk of disease progression and to affect clinical decision making in
MDS.14-17 Preliminary data suggest that mutations in TP53, TET2,
and DNMT3A genes are associated with a high probability of
relapse after HSCT.18
Comprehensive analyses in large patient populations are
warranted to correctly estimate the independent effect of each
mutation on posttransplantation outcome. To address this ques-
tion, we used massively parallel sequencing to examine tumor
samples for coding mutations in 34 recurrently mutated genes in
myeloid neoplasms. Samples were collected from 401 patients with
MDS or MDS/AML before HSCT.
PATIENTS AND METHODS
Patients and Study Design
These investigations were approved by the ethics committee of the
Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. We studied 401
patients who underwent allogeneic HSCT for primary MDS or AML
evolving from MDS (MDS/AML) between 1997 and 2013 and were re-
ported to the Gruppo Italiano Trapianto di Midollo Osseo registry. Di-
agnosis of MDS was made or revised according to the 2008 WHO
criteria.19 Clinical characteristics of patients and transplant procedures are
reported in Table 1.20
Sample Processing, DNA Sequencing, and Mutation Analysis
We analyzed bone marrow mononuclear cells collected at the time of
transplant in patients receiving allogeneic HSCTupfront, and at the time of
remission-induction therapy in those receiving treatment before trans-
plantation. In nine patients, samples at the time of disease relapse after
HSCT were also studied. DNA was isolated from tumor cells using the
Gentra Puregene Blood Kit (Qiagen, Germantown, MD).
A TruSeq Custom Amplicon panel (TSCA; Illumina, San Diego, CA)
targeting complete coding exons and their adjacent splice junctions from
34 genes was designed using Illumina Design Studio software. Genes were
selected based on the available evidence in myeloid neoplasms (Appendix
Table A1, online only). The TSCA panel consisted of 886 amplicons, 425 bp
in length, for a total of 205 kb targeted DNA. Dual-barcoded TSCA li-
braries were created from 250 ng of high-quality DNA according to the
manufacturer’s protocol. Libraries were multiplexed and underwent
23 250–bp paired-end sequencing on a MiSeq sequencing system using
MiSeq Reagent Kit v3 (Illumina).
Mutational analysis of low-performer regions (ie, regions with in-
adequate coverage [, 1003]) was carried out using Nextera XT sample
preparation kit (Illumina), and sequencing reactions were performed using
the MiSeq v2 (2 3 150 bp) chemistry. The resulting average depth of
coverage for the 886 amplicons was 9803. Sequence reads were initially
aligned to the human genome (GRCh37/hg19) using the Burrows-Wheeler
aligner. The Genome Analysis Toolkit (www.broadinstitute.org/gatk/) was
later used to clean up reads and to make alignment data more reliable for
the variant calling (Genome Analysis Toolkit data clean up best practice).
Single nucleotide variants and small insertions and deletions were iden-
tified by MuTect and UnifiedGenotyper, respectively.
Functionally annotated variants were filtered accordingly to the
following criteria. Synonymous variants and variants located outside
protein-coding regions were filtered. Polymorphisms described in
dbSNP (version 138) and in 1000 Genomes Project with a population
frequency . 1% and 0.14%, respectively, were removed. Finally, var-
iants with coverage , 303 and , 10 supporting reads, and vari-
ants with an allelic fraction (VAF) lower than 1%, were filtered. The
remaining variants, evaluated as candidate somatic mutations, were
finally tagged as oncogenic using different criteria based on information
retrieved from literature, sequence conservation, and in silico pre-
diction effect.21-23
Statistical Analysis
Comparison of numerical variables between groups was carried out
using a nonparametric approach (Mann-Whitney test or Kruskal-Wallis
analysis of variance). Comparison of the distribution of categorical
variables in different groups was performed with either Fisher’s exact
test (2 3 2 tables) or the x2 test (larger tables). Overall survival (OS)
was defined as the time between transplantation and death (from any
cause) or last follow-up (for censored observations). When estimating
nonrelapse mortality, any death in the absence of disease relapse was
considered an event. The probability of relapse was estimated con-
sidering transplant as a failure at the time of hematologic relapse (evaluated
according to standardized criteria).24 The cumulative probability of
surviving was estimated using the Kaplan-Meier product limit method.
The cumulative incidence of relapse and nonrelapse mortality were
estimated with a competing-risks approach.25 Univariable and mul-
tivariable survival analyses were performed using Cox proportional
hazards regression. To compare different statistical models, we used the
likelihood ratio test. Analyses were performed using STATA 11.2 SE
(STATA, College Station, TX) and Statistica 7.0 (StatSoft Inc., Tulsa,
OK) software.
RESULTS
Gene Mutations in Patients With MDS and MDS/AML
Receiving HSCT
Oncogenic mutations were identified in 34 genes in the whole
study population. RUNX1 was the most frequently mutated gene
(23%), followed by SRSF2 (17%), ASXL1 (17%), SF3B1 (16%),
KRAS/NRAS (16%), DNMT3A (15%), TP53 (13%), and TET2
(10%) (Fig 1A).
In total, 318 of 401 patients (79%) had at least one on-
cogenic point mutation, whereas cytogenetic studies identified
abnormalities in 149 patients (37%). When sequencing and
cytogenetics were combined, the number of patients with MDS-
related oncogenic lesions increased to 87%. Indeed, 97 patients
had one oncogenic point mutation (24%), 123 had two or three
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mutations (31%), and 98 had greater than four mutations
(24%). No significant relationship was observed between WHO
category (reflecting disease burden) and the prevalence of pa-
tients carrying driver mutation(s). Moreover, the sample quality
and the average depth read in wild-type patients were comparable
to those of mutated cases.
A significantly higher prevalence of mutations in splicing
factors were observed in MDS compared with MDS/AML
(P = .021), whereas mutations in DNA methylators were more
frequent in MDS/AML than in MDS (P = .001; Fig 1B and C). We
then focused on MDS/AML and stratified these 127 patients
according to three distinct genetic subtypes, as previously de-
fined25: secondary-type AML (including patients carrying mu-
tations in SRSF2, SF3B1, U2AF1, ZRSR2, ASXL1, EZH2, BCOR,
or STAG2 genes), TP53-mutated AML, and de novo AML (mainly
including patients with NPM1 mutations, MLL/11q23 and
CBF rearrangements). Accordingly, 55 subjects were classified as
secondary-type AML (43%), 13 as TP53-mutated AML (10%),
and 59 as de novo AML (47%; Fig 1C).
Genetic Predictive Features for the Outcomes of
Allogeneic HSCT in Patients With MDS and MDS/AML
In our study, the number of somatic mutations was found to
have a significant effect on probability of relapse and OS after
HSCT (P , .001 and P = .017, respectively; Fig 2A). We then
examined the hazard ratio (HR) of death associated withmutations
in the genes mutated in $ 5% of patients in this cohort. In
univariable analysis, mutations in RUNX1, ASXL1, IDH1/2, and
TP53 were associated with increased probability of relapse (HR,
1.78 [95% CI, 1.26 to 2.27], P = .001; HR, 1.89 [95% CI, 1.34 to
Table 1. Demographic Data, Clinical Characteristics, and Transplant-Related Features of Patients With MDS or Acute Myeloid Leukemia Evolving From MDS Who
Underwent Allogeneic Hematopoietic Stem-Cell Transplantation (N = 401)
Variable* MDS MDS/AML† Comparison Between MDS and MDS/AML P
Demographic data and clinical characteristics
No. of patients (%) 274 (68) 127 (32)
Age, years, median (range) 54 (18-72) 52 (19-69) NS
Sex, male/female 156 (57)/118 (43) 75 (59)/52 (41) NS
WHO classification
RCUD/RARS/MDS del(5q) 27 (10) —
RCMD 63 (23) —
RAEB-1 69 (25) —
RAEB-2 115 (42) —
Hemoglobin, g/dL, median (range) 9.1 (5.8-11.3) 8.9 (6.2-11.9) NS
Leukocyte count, 3 109/L, median (range) 3.17 (0.2-42.8) 2.71 (0.12-38.9) NS
Neutrophil count, 3 109/L, median (range) 1.9 (0.09-32.3) 1.69 (0.1-9.1) NS
Platelet count, 3 109/L, median (range) 87 (2-862) 71 (3-433) NS
Transfusion dependency‡ 159 (58) 85 (67) NS
IPSS-R risk 260 (95) 119 (94)
Low 47 (18) — , .001
Intermediate 75 (29) 7 (6)
High 96 (37) 64 (54)
Very high 42 (16) 48 (40)
Transplant-related features
Time from diagnosis to HSCT, months (range) 10.1 (2-189.3) 8.9 (2-20.5) NS
Type of donor
Sibling 151 (55) 77 (61) NS
Unrelated donor (MUD)§ 123 (45) 50 (39)
Source of hematopoietic stem cells
Peripheral blood/cord blood 181 (66) 75 (61) NS
Bone marrow 93 (34) 52 (41)
Remission-induction chemotherapy 85 (31) 121 (95) , .001
Complete remission 42 (49) 69 (57) NS
Conditioning regimenk
Standard conditioning regimen 175 (64) 77 (61) NS
Reduced-intensity conditioning 99 (36) 50 (39)
NOTE. All values are expressed as the number of patients (%), unless otherwise specified.
Abbreviations: HSCT, hematopoietic stem-cell transplantation; IPSS-R, revised International Prognostic Scoring System;MDS,myelodysplastic syndromes; MDS/AML,
acute myeloid leukemia evolving fromMDS;MDS (del)5q, MDS associated with isolated del(5q); MUD, matched unrelated donor; NS, not significant; RAEB-1, refractory
anemia with excess blasts-1; RAEB-2, refractory anemia with excess blasts-2; RARS, refractory anemia with ring sideroblasts; RCMD, refractory cytopenia with
multilineage dysplasia; RCUD, refractory cytopenia with unilineage dysplasia
*All variables were analyzed at the time of transplantation in patients undergoing up-front allogeneic HSCT, and at the time of remission-induction chemotherapy in
those receiving treatment before transplantation.
†MDS/AML included patients with AML evolving from MDS, and those affected with RAEB-t (refractory anemia with excess blasts in transformation) according to the
French-American-British classification.
‡Transfusion dependency was defined as having at least one red blood cell transfusion every 8 weeks over a period of 4 months.20
§Criteria for selection of human leukocyte antigen (HLA)–matched unrelated donors before 2002 included low-resolution typing for HLA class I (A, B) and high-resolution
typing for HLA-DRB1. Since 2002, criteria have included high-resolution typing for both HLA class I (A, B, C) and class II alleles (DRB1/3/4/5, DQA1, DPB1).
kThe most frequent conditioning regimens included the following: total body irradiation (TBI) and cyclophosphamide, TBI and fludarabine, busulfan and cyclophos-
phamide, thiotepa and cyclophosphamide, and thiotepa and fludarabine. In most patients, graft-versus-host disease prophylaxis was combined cyclosporine and
methotrexate.
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Fig 1. Mutation patterns observed in patientswithmyelodysplastic syndromes (MDS) and acutemyeloid leukemia evolving fromMDS,whowere treatedwith allogeneic
hematopoietic stem-cell transplantation. (A)Whole patient population (N = 401); (B) patients withMDS diagnosed according toWHO criteria (n = 274); and (C) patients with
acute myeloid leukemia evolving fromMDS (n = 127). The plot represents a graphical summary of the distribution of somatic lesions in sequenced genes across the set of
patients, grouped in categories as labeled in the legend. Columns represent samples and rows represent genes.Mutations are depicted by colored glyphswhose colors are
used to distinguish different pathways, and their number per sample and per gene is summarized on the top and on the right side of the plot, respectively. In panel C, colors
reflect ontogeny specificity of mutated genes, and genetic ontogeny groups are labeled on the top.
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2.56], P, .001; HR, 1.74 [95% CI, 1.17 to 2.38], P = .002; and HR,
1.95 [95% CI, 1.54 to 2.57], P, .001, respectively) and shorter OS
(HR, 1.69 [95% CI, 1.1 to 2.23], P = .008; HR, 1.73 [95% CI, 1.23 to
2.18], P= .003; HR, 1.42 [95%CI, 0.95 to 2.16], P= .04; andHR, 1.92
[95% CI, 1.48 to 2.37], P = .001, respectively; Fig 2B and Table 2).
The prognostic effect of gene mutations was maintained when
considering patients with MDS and patients with MDS/AML
separately (P values ranging from .039 to , .001). RUNX1 mu-
tations were significantly associated with multilineage dysplasia
(P = .012), excess blasts (P = .024), and decreased level of platelets
(P = .031). A borderline association was found between ASXL1
mutations and poor/very poor cytogenetic risk according to IPSS-R
criteria (P = .052). IDH1/2 mutations were associated with excess
blasts (P = .018) and multilineage dysplasia (P = .009). TP53
mutations were associated with poor/very poor cytogenetic risk
(P, .001), transfusion dependency (P = .042), and decreased level
of neutrophils (P = .033).
As a next step, we fitted a Cox multivariate model to evaluate
the prognostic effect of somatic mutations on posttransplantation
outcome, considering as covariates the factors age and sex of re-
cipient; hemoglobin, neutrophil, and platelet levels; percentage of
marrow blasts; cytogenetics (according to IPSS-R criteria), disease
stage at transplantation (complete remission v active/progressive
disease), source of hematopoietic stem cells (peripheral blood v
bone marrow), type of donor (human leukocyte antigen–identical
sibling v matched unrelated donor); and type of conditioning
(reduced-intensity v standard conditioning).
In the analysis performed on patients with MDS, mutations in
ASXL1, RUNX1, and TP53 genes showed an independent effect on
probability of relapse and OS after transplantation (ASXL1: HR,
1.89 [95%CI, 1.41 to 2.46], P = .003 and HR, 1.72 [95%CI, 1.39 to
2.23], P = .008; RUNX1: HR, 1.67 [95% CI, 1.31 to 2.37], P = .020
and HR, 1.59 [95% CI, 1.29 to 2.18], P = .035; TP53: HR, 1.90
[95% CI, 1.52 to 2.39], P = .019 and HR, 1.82 [95% CI, 1.48 to
2.47], P = .022, respectively; Table 2).
To account for the long period of recruitment, we analyzed
the effect of year of transplantation on clinical outcome. Year of
transplantation showed a significant effect on transplant-related
mortality (P = .011) and a borderline effect on OS (P = .062),
whereas probability of relapse was not significantly affected.
We then stratified mutations according to VAF. Patients with
mutated ASXL1, RUNX1, and TP53 genes with VAF # 10% versus
. 10% were 14% versus 86%, 55% versus 45%, and 45% versus
55%, respectively. The negative effect of gene mutations on post-
transplantation outcome was maintained when performing separate
analyses on patients with VAF # 10% versus . 10% (data not
shown).
To verify whether somatic mutations could improve the
prognostic stratification of patients with MDS who underwent
HSCT, we fitted two separate multivariable analyses, including and
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Fig 2. Relationship between (A) number of mutations and (B) type of oncogenic mutations and overall survival of patients with myelodysplastic syndromes (MDS)
receiving allogeneic hematopoietic stem-cell transplantation. (C) Posttransplantation overall survival among patients with acute myeloid leukemia (AML) evolving from
MDS according to genetic ontogeny group. NS = not significant.
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not including ASXL1, RUNX1, and TP53 mutations, respectively,
and compared them using the likelihood ratios test. The model
comparison resulted in a significant P value (P , .001), thus
confirming the importance of accounting for gene mutations in the
prognostic model.
We then focused on patients with MDS/AML. Mutations in
ASXL1, RUNX1, and TP53 genes confirmed an independent
effect on probability of relapse and OS after transplantation
(ASXL1: HR, 2.41 [95% CI, 1.59 to 4.41], P = .029 and HR, 2.09
[95% CI, 1.64 to 3.89], P = .021; RUNX1: HR, 2.46 [95% CI,
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Fig 2. (Continued).
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1.69 to 4.52], P = .038 and HR, 1.96 [95% CI, 1.47 to 4.08],
P = .031; and TP53: HR, 3.12 [95% CI, 1.77 to 5.11], P = .003
and HR, 2.54 [95% CI, 1.61 to 4.09], P = .004, respectively;
Table 2).
We stratified patients with MDS/AML according to three
distinct genetic subtypes (ie, de novo AML [reference group],
secondary-type AML, and TP53-mutated AML).26 Genetic AML
subgroups were significantly associated with a different prob-
ability of relapse and survival after transplantation (P = .003 and
P = .013, respectively; Fig 2C). In multivariable analysis, AML
ontogeny maintained an independent effect on probability of
relapse and survival after transplantation (HR, 1.78 [95% CI,
1.36 to 3.63], P = .028 and HR, 1.74 [95% CI, 1.25 to 3.87],
P = .042, respectively).
Clinical Impact of Somatic Mutations in Patients With
MDS Receiving HSCT, Stratified According to IPSS-R
First, we evaluated the prognostic effect of the IPSS-R score
using a multivariate regression model. In this analysis, focused on
patients with MDS, IPSS-R significantly affected probability of
relapse (HR, 1.53 [95% CI, 1.18 to 2.16], P , .001) and OS (HR,
1.41 [95% CI, 1.11 to 2.05], P = .001). We then introduced somatic
mutations in ASXL1, RUNX1, and TP53 genes as covariables in the
model. Both IPSS-R and gene mutations maintained an inde-
pendent effect on posttransplantation outcome (IPSS-R: proba-
bility of relapse HR, 1.37 [95% CI, 1.02 to 1.99], P , .001 and OS
HR, 1.29 [95% CI, 1.04 to 2.21], P = .001; ASXL1: probability of
relapse HR, 1.95 [95% CI, 1.16 to 3.14], P = .015 and OS HR, 1.69
[95%CI, 1.26 to 2.35], P= .007; RUNX1: probability of relapse HR,
1.72 [95% CI, 0.98 to 2.77 ], P = .041 and OS HR, 1.69 [95% CI,
1.06 to 1.97], P = .017; and TP53: probability of relapse HR, 1.79
[95% CI, 1.25 to 2.59], P = .030 and OS HR, 1.48 [95% CI, 1.08 to
2.37], P = .036).
In prognostic terms, because the HRs of IPSS-R score
and of ASXL1, RUNX1, and TP53 mutations are comparable in
size, the increase in risk resulting from the presence of mu-
tated genes is equivalent to the increase resulting from a one-
step shift into a more advanced IPSS-R risk group. Post-
transplantation outcomes in patients with MDS classified by
IPSS-R and stratified according to the presence of mutations in
ASXL1, RUNX1, and TP53 genes are reported in Fig 3. Ac-
counting for various combinations of a patient’s IPSS-R cate-
gory and mutational status, 5-year probability of survival and
cumulative incidence of relapse after allogeneic HSCT ranged
from 0% to 73% and from 4% to 77%, respectively. Compared
with the IPSS-R–based stratification, when introducing gene
mutations, the prediction of posttransplantation outcome
would significantly change for 34% of patients.
Finally, to verify whether gene mutation could improve
the IPSS-R prognostic stratification of patients with MDS who
underwent allogeneic HSCT, we fitted two separate multi-
variable analyses including and not including gene mutations
as covariables, respectively, and compared them using the
likelihood ratios test. The model comparison resulted in
a significant P value (P , .001), thus confirming the impor-
tance of accounting for gene mutations in the prognostic
model.
Mutation Pattern at Disease Relapse After HSCT in
Patients With MDS and MDS/AML
We used massively parallel sequencing to examine paired
tumor samples collected from nine patients before HSCTand at
the time of disease relapse after the procedure. Different types
of clonal evolution occurred at relapse. In seven patients, the
founder clone recurred, whereas in two patients a subclone of
the founder clone escaped and expanded at relapse. In all
patients, additional mutations not detected at diagnosis were
observed at the time of relapse (Table 3). Focusing on the three
genes associated with negative posttransplantation outcomes
in our study, in patient 3, the founder clone carrying RUNX1
Table 2. Prognostic Value of Gene Mutations for Posttransplantation Outcomes in Univariable and Multivariable Analyses
Analysis Type
Probability of Relapse Overall Survival
HR 95% CI P HR 95% CI P
Univariable analysis
Whole study population
Variable
ASXL1 1.89 1.34 to 2.56 , .001 1.73 1.23 to 2.18 .003
RUNX1 1.78 1.26 to 2.27 .001 1.69 1.1 to 2.23 .008
IDH1/2 1.74 1.17 to 2.38 .002 1.42 0.95 to 2.16 .04
TP53 1.95 1.54 to 2.57 , .001 1.92 1.48 to 2.37 .001
Multivariable analysis
Patients with MDS
Variable
ASXL1 1.89 1.41 to 2.46 .003 1.72 1.39 to 2.23 .008
RUNX1 1.67 1.31 to 2.37 .02 1.59 1.29 to 2.18 .035
TP53 1.90 1.52 to 2.39 .019 1.82 1.48 to 2.47 .022
Patients with MDS/AML
Variable
ASXL1 2.41 1.59 to 4.41 .029 2.09 1.64 to 3.89 .021
RUNX1 2.46 1.69 to 4.52 .038 1.96 1.47 to 4.08 .031
TP53 3.12 1.77 to 5.11 .003 2.54 1.61 to 4.09 .004
Abbreviations: HR, hazard ratio; MDS, myelodysplastic syndromes; MDS/AML, acute myeloid leukemia evolving from MDS.
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mutation recurred at the time of relapse, whereas in patients 7
and 9, mutations of RUNX1 and ASXL1 (both with low VAF
before transplant) expanded at the time of disease recurrence,
respectively.
DISCUSSION
Disease relapse is a common cause of HSCT failure in patients
with MDS or MDS/AML.8-11 We tested the hypothesis that driver
mutations may have an effect in predicting posttransplantation
outcomes in these patients.18 Mutations in ASXL1, RUNX1, and
TP53 genes were found to be independent predictors of re-
lapse and OS after HSCT. The integration of mutations into
currently available predictive models was found to increase the
ability to capture prognostic information at the individual
patient level.27
In this study, gene sequencing significantly increased the
proportion of patients with information on disease biology with
respect to conventional cytogenetics.14 The genotype of MDS
treated with HSCTwas consistent with a patient subgroup at high
risk of clonal evolution, as indicated by a decreased frequency of
SF3B1 mutations and increased frequency of mutations in tran-
scription factors (RUNX1) and TP53 with respect to the whole
MDS population.14 We observed in addition that at least three
distinct genetic subtypes may account for unique MDS/AML
clinical phenotypes: secondary-type AML (including patients
carrying mutations in MDS-related genes), TP53-mutated AML,
and de novo AML,26 thus suggesting that gene ontology may
provide more objective diagnostic criteria with respect to clinical
classification in these patients. Finally, massively parallel se-
quencing provided information on clonal evolution occurring at
relapse after HSCT. In some patients, the founder clone recurred,
whereas in other patients a subclone of the founder clone escaped
and expanded at relapse.28 In all patients, additional mutations not
detected at the time of diagnosis were observed at the time of
relapse.
We provided evidence of clinical utility in considering mu-
tation screening to predict survival after transplantation in patients
with MDS and MDS/AML. In clinical practice, IPSS-R score
identified four groups of patients with different probabilities of
survival and disease relapse after HSCT.12 A major contribution to
the improvement of posttransplantation outcome prediction by
IPSS-R was provided by the refinement of the prognostic role of
chromosomal abnormalities.7 Nevertheless, cytogenetics is not
informative in a large proportion of patients and reveals secondary
genetic events.4 Accounting for various combinations of a patient’s
IPSS-R category and mutational status of ASXL1, RUNX1, and
TP53 genes, 5-year probability of survival and relapse after allo-
geneic HSCT ranged from 0% to 73% and from 4% to 77%,
respectively. In direct comparison, a predictive model accounting
for gene mutations was found to be more likely to capture
prognostic information with respect to IPSS-R alone.
In patients with MDS/AML, we observed that gene ontology
predicts survival after transplantation. Secondary-type AML was
associated with a lower probability of survival after transplant
compared with patients with de novo AML. Moreover, TP53
mutations identified a group of patients with dismal outcomes
after transplantation.
Overall, these results serve as a proof of concept that the
integration of somatic mutations significantly increase the ability
to capture prognostic information in patients withMDS andMDS/
AML who are receiving allogeneic HSCT, and may provide a basis
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Fig 3. Posttransplantation overall survival of patients with myelodysplastic
syndromes classified by the revised International Prognostic Scoring System
(IPSS-R) and stratified according to the presence of mutations in the ASXL1,
RUNX1, and TP53 genes.
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for improving clinical decision making.4,27 Possible interventions
in patients with high risk of disease relapse after HSCTaccording to
genotype may include the anticipation of the transplant procedure
in early disease phase, the use of innovative conditioning regimens
to increase the probability of eradicating the MDS clone, and
prophylaxis of disease recurrence after transplantation by donor
leukocyte infusions and targeted/novel therapies.29,30
There are potential weaknesses in our work, mainly related to
the retrospective nature of this registry-based study. These include
patient selection, missing data in a proportion of patients, a long
period of recruitment, and different types of transplantation and
of pretransplantation treatment. Moreover, in the absence of a
matched control sample, it is challenging to distinguish with
perfect accuracy between somatic and germline variants. Despite
these limitations, clinical and hematologic data were available in
the great majority of the original patient population, and analyses
were adjusted for all known potential confounding factors. Fur-
thermore, samples for mutation screening were homogeneously
collected from bone marrow before treatment, and the landscape
of truly somatic mutations in tested genes has been well estab-
lished from large-scale genomics studies,2,3,14-16,18 allowing
confident predictions to be made. Although we are aware that
a prospective validation of our observations is needed, we believe
that the findings of this study may contribute to improving
prognostic counseling of patients with MDS and the design of
clinical trials.
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Appendix
Table A1. Target Gene List
Gene Pathway NCBI ID Position
SF3B1 RNA splicing 23451 2q33.1
SRSF2 RNA splicing 6427 17q25.1
U2AF1 RNA splicing 7307 21q22.3
ZRSR2 RNA splicing 8233 Xp22.1
DNMT3A DNA methylation 1788 2p23
IDH1 DNA methylation 3417 2q33.3
IDH2 DNA methylation 3418 15q26.1
TET2 DNA methylation 54790 4q24
ASXL1 Chromatin and histones 171023 20q11.1
BCOR Chromatin and histones 54880 Xp11.14
EP300 Chromatin and histones 2033 22q13
EZH2 Chromatin and histones 2146 7q35-36
KDM6A Chromatin and histones 7403 Xp11.2
CBL Signaling 867 11q23.3
CSF3R Signaling 1441 1p35-p34.3
FLT3 Signaling 2322 13q12
JAK2 Signaling 3717 9p24
KIT Signaling 3815 4q12
KRAS Signaling 3845 12p12.1
NF1 Signaling 4763 17q11.2
NRAS Signaling 4893 1p13.2
PTPN11 Signaling 5781 12q24.1
RIT1 Signaling 6016 1q22
CEBPA Transcriptional regulation 1050 19q13.1
CUX1 Transcriptional regulation 1523 7q22.1
ETV6 Transcriptional regulation 2120 12p13.2
NPM1 Transcriptional regulation 4869 5q35
PHF6 Transcriptional regulation 84295 Xq26.2
RUNX1 Transcriptional regulation 861 21q22.3
STAG2 Cohesin complex 10735 Xq25
TP53 Tumor suppressor gene 7157 17p13.1
WT1 Tumor suppressor gene 7490 1p13
SETBP1 Genetic cancer susceptibility 26040 18q21.1
ETNK1 Metabolic process 55500 12p12.1
Abbreviations: ID, identification; NCBI, National Center for Biotechnology
Information.
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